Once again OBJ announce another global collaboration partnership yet to be factored in with all the other recent announcements neglected by our market.
16/08/2011: Pain Patch Development Program - No change in sp 23/08/2011: US Patent Office Allows Dermaportation Patent - No change in sp 18/05/2012: P&G Enters Joint Development Agreement - No change in sp 30/11/2012: Technology Partner to Pfizer (AGM) - sp dropped - 13.33% 22/02/2013: Exclusive Collaboration Agreement with Philosophy - No change in sp
Management have clearly indicated that OBJ's partners do not wish to draw attention from the competition to their development plans. The companies conservatism in its market announcements are certainly no reflection on a management team incapable of promoting the company - I believe it's all quite intentional, and if the elaborate admission of OBJ's Technology Partnership with the "World's Largest Pharmaceutical Company" without naming the obvious wasn't evidence enough, one only needs to look back through the history of OBJ's announcements to find that management did quite a superb job of promoting itself right up until the first of the majors came on the scene in 2006
The market have clearly determined that OBJ company have lost over - 80% of its value since the announcement of fully funded collaboration and development agreements with both the largest pharmaceutical and largest consumer goods company on the planet, in addition to GSK Consumer Healthcare in the UK, and GlaxoSmithKline Pharmaceutical Group in the US, 3M, Philosophy, an undisclosed Top 5 Global Prestige Cosmetic Company, undisclosed FMCG 1 (US) and another undisclosed FMCG based in the UK.
Two simple words stood out for me in today's announcement:
"The Agreement defines the terms upon which OBJ and Philosophy will collaborate to develop, program and manufacture eSkin systems with the proprietary delivery fields necessary to control a number of key ingredients used 'widely' by Philosophy."
That one needs no defining.
"The recent allowance of the Dermaportation patent by the European Patent Office and the granting of the same patent by the US Patent Office in 2012 are 'fundamental' to the collaboration.
Imo, this again raises the question for the potential of the imminent EPO grant to trigger an announcement that may be material to the value of the companies securities.
On a lighter note, Philosophy have chosen a rather interesting choice of name for it's latest product offerings in 'anti-wrinkle' skincare creams, especially when considering there is currently not one cosmetically marketed anti-wrinkle cream product being sold on the planet today which has been scientifically proven to actually reduce wrinkles... Philosophy's latest range is called, "full of promise"
OBJ Price at posting:
1.9¢ Sentiment: LT Buy Disclosure: Held
(20min delay)